Drug-maker Granules India’s net profit declined 31 per cent to ₹101 crore in the quarter ended December 31, 2021, against ₹147 crore in the corresponding quarter of the previous year. 

The total revenue of the Hyderabad-based company, however, increased 18 per cent to ₹997 crore from ₹845 crore in the same period last year, according to a release.

Commenting on the results, Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India, said, “We are slowly getting back to the normal as is evident from the revenue growth which came in despite the continuing disruptions and challenging environment such as raw material price increase and unstable supply from China, among other supply constraints.’‘

Also read

US FDA has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc

The company is expecting the situation to improve in the coming quarters and would remain focused on execution and agile to the market opportunities, he added. 

Granules is “strengthening management capabilities and investing in R&D infrastructure, scientific talent, and  partnerships in science & technology which will lead to sustainability, leadership, backward integration and focus on quality of our portfolio,” the release added,

Related Topics